NCT07625943Recruiting
HYPOfractionated RadioTherapy in Cervical Cancer
Hypofractionated Radiotherapy in Cervical Cancer: A Non-inferiority Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
The study is a prospective, randomized, non-inferiority clinical trial which will test whether a short course of radiation treatment (hypofractionation) for cervical cancer works as well as the standard longer course. Cervical cancer is one of the most common cancers in women in India, and many patients have trouble completing treatment because it takes several weeks and requires many hospital visits. In this trial, females with locally advanced cervical cancer will be randomly assigned to one of two treatment groups. One group will receive the standard radiation schedule with External Beam RadioTherapy (EBRT) over about 5 weeks, weekly cisplatin chemotherapy, and brachytherapy. The other group will receive a shorter, hypofractionated external beam radiotherapy schedule over about 3 weeks, the same chemotherapy, and brachytherapy. Researchers will compare the two groups to see whether the hypofractionated schedule is non-inferior to the standard radiation therapy schedule. The main outcomes will be tumor control in the pelvis, side effects, survival, and quality of life. If the hypofractionated schedule meets the non-inferiority limit, it could reduce treatment time, improve patient convenience, and help more people receive treatment in busy cancer centers in emerging countries.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 396 (estimated)
- First submitted
- 27 May 2026
- Start date
- 15 Jan 2026
- Primary completion date
- 15 Jul 2029
- Lead sponsor
- All India Institute of Medical Sciences
- Diseases
- Cervical cancer
- NCT number
- NCT07625943
What you commit to
- Study type: Interventional
- Planned participants: 396
- From 15 Jan 2026 to the primary completion date, 15 Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior pelvic radiotherapy or prior chemotherapy for cervical cancer.
Other illness
- Inflammatory bowel disease.
- Synchronous malignancy.
- Any serious medical condition that would interfere with protocol treatment or follow-up.
Other
- ECOG performance status 3 or higher.
- FIGO stage IIIC2, IVA, or IVB.
- Hydronephrosis.
- Pregnancy.
Who the study is looking for
- Female participants aged 18 to 65 years.
- Histopathologically confirmed cervical cancer.
- FIGO stage IB3 to IIIC1.
- Suitable for definitive concurrent chemoradiation.
- ECOG performance status 0 to 2.
- Adequate hematological, renal, and hepatic function.
- Able and willing to provide informed consent.
Age in the registry: 18 years to 65 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India Coordinator of this site? Confirm its status | New Delhi | India | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.